Founder, President and Chief Executive Officer, Kymera Therapeutics, Inc.
Search every verified Nello Mainolfi interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a recent conversation marking Kymera Therapeutics' tenth anniversary, Mainolfi reflected on the company's founding and its evolution in the field of targeted protein degradation. He discussed the early biotech landscape of 2015-2016, noting the enthusiasm for "smart chemistry plays" and the initial skepticism about whether heterobifunctional degraders could behave like traditional small molecules. Mainolfi stated his belief that chemistry problems are solvable, whereas biology problems are often not, and described Kymera's development of unpublished "new rules" for the property ranges required across its programs. Mainolfi also discussed the company's future ambitions, expressing a hope that Kymera will become a global commercial-stage company generating a new generation of medicines. He characterized the path to becoming a multi-billion dollar company as difficult, requiring luck, skill, and strategy, but identified the hardest step ahead as transitioning into a global commercial company with approved medicines in multiple markets. He additionally shared a key learning from Kymera's work: the importance of identifying specific ligands to targets without relying on existing ones, noting that high specificity in degraders addresses a major challenge given the technology's catalytic nature.
Kymera founders Nello Mainolfi and Bruce Booth revisit the company’s earliest days and the founding thesis behind what they set out to build. Ten years later, they look back at the early choices that shaped Kymera and how those decisions have stood the test of time. Explore Kymera’s pipeline and learn more at https://www.kymeratx.com
In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech founder and discusses the opportunities and lessons learned from building a company at the forefront targeted protein degradation. Episode Timestamps; 00:00 Welcome to Idea Collider 00:18 Kymera 2026 Catalysts 02:33 De Risking with Degraders 02:54 Targeted Protein Degradation 101 06:20 KT-621 STAT6 Degrader 08:16 Rethinking Type 2 Disease Treatment 12:21 Nello’s Path to CEO 16:32 Building a Standalone Biotech 23:19 Pa…
--------- Kymera Therapeutics, Inc KYMR Q3 2025 Earnings Call --------- In this video, we’ll cover the latest quarterly earnings results, key financial metrics, and business highlights from the most recent reporting period. 🔔 Don’t forget to subscribe and follow us on X for more updates: https://x.com/Fyfull2 Disclaimer: This video includes segments from official corporate earnings calls and presentations, used for educational and informational purposes under fair use (Section 107, U.S. Copyright Act). No affiliation or endorsement by the companies mentioned is implied. All content rights…
Kymera Therapeutics has a clear mission: to transform immunology with targeted protein degraders that enable “oral drugs with biologics-like activity,” CEO Nello Mainolfi told The BioCentury Show. A pioneer in one of biopharma’s most closely watched new therapeutic modalities, Kymera is now over nine years into its story, with multiple pharma partnerships and a wholly owned pipeline, including a STAT6 degrader that produced promising data in June. In conversation with BioCentury’s Selina Koch, Mainolfi discusses the appeal of degraders, the rationale for choosing glues or heterobifunctional de…
Nello Mainolfi, CEO of Kymera Therapeutics, on targeted protein degrading small molecule drugs.
We're forging meaningful partnerships to drive innovation and bring new treatments to patients in need. In this instalment of our 'Partner Spotlight' series, Naimish Patel talks with Nello Mainolfi, founder and CEO of Kymera Therapeutics, to highlight the exciting potential of targeted protein degradation therapies in immunology and inflammation.
GoINPHARMA™ meets Dr. Nello Mainolfi, founder and CTO of Kymera Therapeutics LLC, who explains their innovative technology to target elusive protein whose dis-regulation drives many diseases from cancer to neurodegenerative disease to autoimmune disease. A short transcript of the interview can be read here: https://www.goinpharma.com/en/intervi...
Sign in to search the full transcript archive, filter by topic, and access every quote from Nello Mainolfi.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans